Jiangsu Nhwa Pharmaceutical: Q3 2024 saw double-digit revenue and profit growth, with robust cash flow and rising EPS

About this update from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Q3 2024 revenue grew 10.07% and net profit rose 14.74% year-over-year, with strong cash flow and higher EPS. Asset and equity growth were supported by increased investment and a stock incentive plan.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A